FX.co ★ Bayer's Elinzanetant Meets Primary, Secondary Endpoints In Phase III OASIS 4 Breast Cancer Study

Bayer AG (BAYRY.PK) announced on Thursday that its non-hormonal drug, Elinzanetant, achieved all primary and secondary endpoints in the Phase III OASIS 4 study. This research evaluated the drug's effects on women with breast cancer or those at high risk of developing the disease.

The study, which was double-blind, randomized, and placebo-controlled, took place across multiple centers. It focused on assessing the safety and effectiveness of Elinzanetant in treating moderate to severe vasomotor symptoms, commonly referred to as hot flashes.

The Berlin-based company reported that Elinzanetant successfully reduced both the frequency and severity of these symptoms, achieving statistically significant results. Furthermore, Elinzanetant, an oral dual antagonist targeting neurokinin-1 and 3 receptors, also demonstrated improvements in sleep disturbances and menopause-related quality of life.